Xiuzhen Xie1,2, Kun Song1, Baoxia Cui1, Jie Jiang1, Xingsheng Yang3, Beihua Kong1. 1. Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, 107 Wenhuaxi Road, Jinan, 250012, People's Republic of China. 2. Department of Obstetrics and Gynecology, 2nd Affiliated Hospital of Shandong University of Traditional Chinese Medicine, 1 Jingba Road, Jinan, 250001, People's Republic of China. 3. Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, 107 Wenhuaxi Road, Jinan, 250012, People's Republic of China. yangxingsheng2017@163.com.
Abstract
OBJECTIVE: To explore differences in prognosis between adenocarcinoma (AC) and squamous cell carcinoma (SCC) and to explore feasibility of ovarian preservation in stage IB-IIA cervical cancer (CC). MATERIALS AND METHODS: Medical records of 810 patients (682 SCC + 128 AC) with stage IB-IIA CC were reviewed. Clinical and pathological characters of the two groups were compared using the chi-squared test. Kaplan-Meier survival analysis was used in univariate analysis of prognostic factors. Multivariate analysis of prognostic factors was conducted by the Cox hazards regression model. RESULTS: The incidence of LVSI (lymphovascular space invasion) and poor cell differentiation in SCC patients was higher than that in AC patients (23.90% vs. 8.59%, P < 0.05; and 54.25% vs. 28.91%, P < 0.05). Results of univariate analysis showed that cell differentiation, clinical stage, lymph node metastasis (LNM), ovarian metastasis (OM), parametrial involvement (PI), LVSI, depth of stromal invasion, and tumor size were related to the prognosis of patients with stage IB-IIA CC (P < 0.05). Results of multivariate analysis showed that cell differentiation, clinical stage, and LNM were independent prognostic factors for patients with stage IB-IIA CC. There was no difference in 5-year survival rate between SCC patients and AC patients (87.3% vs. 82.4%; P > 0.05). In AC patients, there was no difference in the 5-year survival rate between patients with ovarian retention and patients with bilateral ovariectomy (75% vs. 86.6%; P > 0.05). CONCLUSIONS: In stage IB-IIA CC, there is no difference in prognosis between AC and SCC. The ovaries of stage IB-IIA1 AC patients under age 45 might be preserved.
OBJECTIVE: To explore differences in prognosis between adenocarcinoma (AC) and squamous cell carcinoma (SCC) and to explore feasibility of ovarian preservation in stage IB-IIA cervical cancer (CC). MATERIALS AND METHODS: Medical records of 810 patients (682 SCC + 128 AC) with stage IB-IIA CC were reviewed. Clinical and pathological characters of the two groups were compared using the chi-squared test. Kaplan-Meier survival analysis was used in univariate analysis of prognostic factors. Multivariate analysis of prognostic factors was conducted by the Cox hazards regression model. RESULTS: The incidence of LVSI (lymphovascular space invasion) and poor cell differentiation in SCC patients was higher than that in AC patients (23.90% vs. 8.59%, P < 0.05; and 54.25% vs. 28.91%, P < 0.05). Results of univariate analysis showed that cell differentiation, clinical stage, lymph node metastasis (LNM), ovarian metastasis (OM), parametrial involvement (PI), LVSI, depth of stromal invasion, and tumor size were related to the prognosis of patients with stage IB-IIA CC (P < 0.05). Results of multivariate analysis showed that cell differentiation, clinical stage, and LNM were independent prognostic factors for patients with stage IB-IIA CC. There was no difference in 5-year survival rate between SCC patients and AC patients (87.3% vs. 82.4%; P > 0.05). In AC patients, there was no difference in the 5-year survival rate between patients with ovarian retention and patients with bilateral ovariectomy (75% vs. 86.6%; P > 0.05). CONCLUSIONS: In stage IB-IIA CC, there is no difference in prognosis between AC and SCC. The ovaries of stage IB-IIA1 AC patients under age 45 might be preserved.
Authors: John H Farley; Kimberly W Hickey; Jay W Carlson; G Scott Rose; Edward R Kost; Terry A Harrison Journal: Cancer Date: 2003-05-01 Impact factor: 6.860
Authors: H M Shingleton; M C Bell; A Fremgen; J S Chmiel; A H Russell; W B Jones; D P Winchester; R E Clive Journal: Cancer Date: 1995-11-15 Impact factor: 6.860
Authors: Lenny Gallardo-Alvarado; David Cantú-de León; Rebeca Ramirez-Morales; Gabriel Santiago-Concha; Salim Barquet-Muñoz; Rosa Salcedo-Hernandez; Cinthya Reyes; Sandra Perez-Alvarez; Delia Perez-Montiel; Carlos Perez-Plasencia; Elizabeth Trejo-Duran; Juan Pablo Galicia Journal: BMC Cancer Date: 2022-04-13 Impact factor: 4.430
Authors: Alma D Campos-Parra; Milagros Pérez-Quintanilla; Antonio Daniel Martínez-Gutierrez; Delia Pérez-Montiel; Jaime Coronel-Martínez; Oliver Millan-Catalan; David Cantú De León; Carlos Pérez-Plasencia Journal: Curr Oncol Date: 2022-07-05 Impact factor: 3.109